{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:56:45Z","timestamp":1784077005272,"version":"3.55.0"},"reference-count":33,"publisher":"Georg Thieme Verlag KG","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Due to their widespread use, testing for direct oral anticoagulants (DOACs) has become urgent in certain clinical situations. Screening based on widely available, rapid, and simple hemostasis assays such as prothrombin time, activated partial thromboplastin time, or even diluted Russel Viper venom time may provide sufficient evidence of \u201cover-coagulation\u201d and could be used \u201cin small\/peripheral\/spoke laboratories\u201d as an emergency strategy, but is not thought to be reliable for driving clinical decision making. Given their good correlation with plasma concentration, urine dipsticks may be considered a valuable alternative for emergency screening, although their performance is dependent on renal function, may vary depending on the time since the last urination, and there may be problems of interfacing with the laboratory\/hospital information system. Separation methods based on liquid chromatography and mass spectrometry may be clinically questionable, since they measure the concentration rather than the actual inhibitory effect of DOACs, are relatively expensive, cumbersome and time consuming, and therefore seem unsuitable for most conditions requiring urgent clinical decision making. A proposed approach therefore involves establishing a network of routine clinical laboratories, designating a reference center where DOAC tests could be available 24\/7, establishing a clear diagnostic care pathway for ordering the tests from the laboratory and standard operating procedures for performing them, the use of the diluted thrombin time for dabigatran and anti-FXa assays (drug-calibrated) for rivaroxaban, apixaban, and edoxaban, as well as providing expert advice throughout the testing process, from ordering to interpretation of results.<\/jats:p>","DOI":"10.1055\/s-0044-1782196","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T23:49:03Z","timestamp":1709941743000},"page":"1114-1122","source":"Crossref","is-referenced-by-count":8,"title":["Pearls and Pitfalls in the Measurement of Direct Oral Anticoagulants"],"prefix":"10.1055","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9523-9054","authenticated-orcid":false,"given":"Giuseppe","family":"Lippi","sequence":"additional","affiliation":[{"name":"Section of Clinical Biochemistry, School of Medicine, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2103-1661","authenticated-orcid":false,"given":"Emmanuel J.","family":"Favaloro","sequence":"additional","affiliation":[{"name":"Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Sydney Centres for Thrombosis and Haemostasis, NSW Health Pathology, Westmead Hospital, Westmead, NSW, Australia"},{"name":"Faculty of Science and Health, Charles Sturt University, Wagga Wagga, NSW, Australia"},{"name":"School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Westmead Hospital, Westmead, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"issue":"08","key":"ref1","first-page":"e93","article-title":"Heart Disease and Stroke Statistics-2023 Update: a report from the American Heart Association","volume":"147","author":"C W Tsao","year":"2023","journal-title":"Circulation"},{"issue":"38","key":"ref2","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.2174\/1381612825666190925163827","article-title":"A brief review of cardiovascular diseases, associated risk factors and current treatment regimes","volume":"25","author":"G D Flora","year":"2019","journal-title":"Curr Pharm Des"},{"issue":"02","key":"ref3","first-page":"175","article-title":"The evolution of anticoagulant therapy","volume":"14","author":"M Franchini","year":"2016","journal-title":"Blood Transfus"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1055\/s-0042-1756702","article-title":"Letter to the Editor: 10-year evolution in worldwide usage of anticoagulant drugs","volume":"49","author":"G Lippi","year":"2023","journal-title":"Semin Thromb Hemost"},{"issue":"08","key":"ref5","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/j.1538-7836.2005.01374.x","article-title":"New anticoagulants","volume":"3","author":"J I Weitz","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref6","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2174\/1389200218666170417124035","article-title":"Laboratory monitoring or measurement of direct oral anticoagulants (DOACs): advantages, limitations and future challenges","volume":"18","author":"E J Favaloro","year":"2017","journal-title":"Curr Drug Metab"},{"key":"ref7","volume-title":"Screening in Chronic Disease","author":"A S Morrison","year":"1992","edition":"2nd ed."},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"G F Tomaselli","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","article-title":"Perioperative management of patients who are receiving a direct oral anticoagulant","volume":"179","author":"J D Douketis","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"15","key":"ref10","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1182\/bloodadvances.2020002335","article-title":"Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure","volume":"4","author":"J R Shaw","year":"2020","journal-title":"Blood Adv"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1515\/cclm-2014-0767","article-title":"Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?","volume":"53","author":"G Lippi","year":"2015","journal-title":"Clin Chem Lab Med"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.thromres.2015.05.001","article-title":"Direct oral anticoagulants (DOACs) in the laboratory: 2015 review","volume":"136","author":"D M Adcock","year":"2015","journal-title":"Thromb Res"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/bjh.13187","article-title":"Normal prothrombin times in the presence of therapeutic levels of apixaban\u2013in-vivo experience from King's College Hospital","volume":"169","author":"J P Patel","year":"2015","journal-title":"Br J Haematol"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.chest.2017.09.047","article-title":"Are screening tests reliable to rule out direct oral anticoagulant plasma levels at various thresholds (30, 50, or 100\u2009ng\/mL) in emergency situations?","volume":"153","author":"A Jabet","year":"2018","journal-title":"Chest"},{"issue":"08","key":"ref15","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1055\/a-1450-8178","article-title":"2021 Update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants","volume":"121","author":"J Douxfils","year":"2021","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jth.13912","article-title":"Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians","volume":"16","author":"J Douxfils","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pathol.2015.11.025","article-title":"The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples","volume":"48","author":"R Bonar","year":"2016","journal-title":"Pathology"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/PAT.0000000000000252","article-title":"The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples","volume":"47","author":"R Bonar","year":"2015","journal-title":"Pathology"},{"issue":"08","key":"ref19","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/jth.14829","article-title":"Unveiling the complex effects of direct oral anticoagulants on dilute Russell's viper venom time assays","volume":"18","author":"A Hillarp","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/s-0038-1668098","article-title":"Detecting anti-IIa and anti-Xa direct oral anticoagulant (DOAC) agents in urine using a DOAC Dipstick","volume":"45","author":"J Harenberg","year":"2019","journal-title":"Semin Thromb Hemost"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1055\/s-0039-1700545","article-title":"Accuracy of a rapid diagnostic test for the presence of direct oral factor Xa or thrombin inhibitors in urine-a multicenter trial","volume":"120","author":"J Harenberg","year":"2020","journal-title":"Thromb Haemost"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1076029621993550","DOI":"10.1177\/1076029621993550","article-title":"Performance characteristics of DOAC Dipstick in determining direct oral anticoagulants in urine","volume":"27","author":"J Harenberg","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"issue":"03","key":"ref23","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1055\/s-0041-1732437","article-title":"Detection of direct oral anticoagulants in patient urine samples by prototype and commercial test strips for DOACs - a systematic review and meta-analysis","volume":"5","author":"A Martini","year":"2021","journal-title":"TH Open"},{"issue":"09","key":"ref24","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1055\/a-1753-2748","article-title":"DOAC Dipstick testing can reliably exclude the presence of clinically relevant DOAC concentrations in circulation","volume":"122","author":"S Margeti\u0107","year":"2022","journal-title":"Thromb Haemost"},{"issue":"08","key":"ref25","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1055\/a-2261-1811","article-title":"Algorithm for rapid exclusion of clinically relevant plasma levels of DOACs in patients using the DOAC Dipstick. An expert consensus paper","volume":"124","author":"J Harenberg","year":"2024","journal-title":"Thromb Haemost"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.aca.2019.03.061","article-title":"Liquid chromatographic methods for the determination of direct oral anticoagulant drugs in biological samples: a critical review","volume":"1076","author":"F Gouveia","year":"2019","journal-title":"Anal Chim Acta"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s11239-021-02596-z","article-title":"Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC-MS\/MS","volume":"53","author":"L Br\u00fcckner","year":"2022","journal-title":"J Thromb Thrombolysis"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1055\/s-0036-1597296","article-title":"Laboratory assessment of direct oral anticoagulants","volume":"43","author":"J Douxfils","year":"2017","journal-title":"Semin Thromb Hemost"},{"issue":"09","key":"ref29","first-page":"1349","article-title":"Paramagnetic micro-particles as a tool for rapid quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma by UHPLC-MS\/MS","volume":"55","author":"M HJ Wiesen","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/978-1-4939-7196-1_18","article-title":"Measuring direct oral anticoagulants","volume":"1646","author":"R C Gosselin","year":"2017","journal-title":"Methods Mol Biol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cca.2018.08.017","article-title":"Measurement of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma using automated online solid-phase extraction combined with ultra-performance liquid chromatography-tandem mass spectrometry and its comparison with coagulation assays","volume":"486","author":"J Kuhn","year":"2018","journal-title":"Clin Chim Acta"},{"key":"ref32","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-443-18649-3.00014-8","volume-title":"Therapeutic drug monitoring of selected direct oral anticoagulants","author":"E J Favaloro","year":"2024"},{"issue":"07","key":"ref33","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/PAT.0b013e32834bf5f4","article-title":"Laboratory testing of anticoagulants: the present and the future","volume":"43","author":"E J Favaloro","year":"2011","journal-title":"Pathology"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1782196.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:13:32Z","timestamp":1730801612000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1782196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":33,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2024,10,11]]},"published-print":{"date-parts":[[2024,11]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1782196","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,8]]}}}